Scientific Sessions 2026 Daily News: Monday, Nov. 9

3 #ScientificSessions26 ScientificSessions.org Late-breaking trials challenge conventional treatments to cardiovascular disease Starting with a statin alone or with statin-ezetimibe led to similar outcomes when LDL-C goals were actively pursued In secondary prevention, whether to initiate statin monotherapy or combination therapy is an everyday decision clinicians face. Rather than the initial regimen itself, what matters most is actively adjusting lipid-lowering therapy in a targetdirected manner to achieve the LDL-C goal, according to “StatinEzetimibe Combination Therapy vs. Statin Monotherapy in Patients With Atherosclerotic Cardiovascular Disease: Prespecified Second Randomization of the Ez-PAVE Trial.” The primary Ez-PAVE multicenter open-label trial randomized 3,048 adults with ASCVD 1:1 to an intensive LDL-C target of <55 mg/ dL or a conventional LDL-C target <70 mg/dL and found that targeting an LDL cholesterol level of <55 mg/ dL resulted in a reduced risk of cardiovascular events at three years. A prespecified second randomization simultaneously compared statinezetimibe combination therapy (1,525 patients) with statin monotherapy (1,523 patients) as an initial lipid-lowering strategy in both LDL-C target groups. In the statin-ezetimibe combination and monotherapy groups, the statin dose was determined according to each patient’s baseline LDL-C level and assigned LDL-C target. In the combination therapy group, patients received a fixed-dose combination of rosuvastatin and ezetimibe 10 mg. During follow-up, lipid-lowering therapy was adjusted according to a predefined protocol to achieve the assigned LDL-C target. In the statin monotherapy group, ezetimibe was added during follow-up in 34.3% of patients in the intensive-targeting group and 24.8% of patients in the conventional-targeting group. The statin-ezetimibe combination therapy produced greater LDL-C lowering than statin monotherapy, and a higher proportion of patients in the combination group reached lower LDL-C levels. However, the rate of the primary outcome, a composite of major cardiovascular events at three years, did not differ significantly between the statin-ezetimibe combination therapy and statin monotherapy groups. The primary outcome occurred in 8.5% of patients in the statin-ezetimibe combination group and 7.9% of patients in the statin monotherapy group. Byeong-Keuk Kim, MD, PhD “The findings suggest that when LDL-C targets are actively pursued and therapy is adjusted accordingly, clinical outcomes are similar whether treatment begins with combination therapy or with a statin alone,” said co-investigator ByeongKeuk Kim, MD, PhD, professor of cardiology at Yonsei University College of Medicine and director of the Cardiovascular Intervention Room at Severance Cardiovascular Hospital in Seoul, South Korea. “When LDL-C levels are monitored and therapy is adjusted to reach the treatment goal, starting with statin monotherapy and adding ezetimibe as needed appears to be a reasonable strategy, with clinical outcomes comparable to those of upfront combination therapy.” Kim noted that the study’s findings support the goal-directed approach emphasized in the “2026 ACC/AHA/AACVPR/ABC/ ACPM/ADA/AGS/APhA/ASPC/ NLA/PCNA Guideline on the Management of Dyslipidemia,” which reintroduced LDL-C goals for patients with ASCVD and recommends adding ezetimibe when maximally tolerated statin therapy doesn’t achieve these goals. The study was published in Circulation following the presentation. Discontinuation of statin therapy for primary prevention was noninferior to continuation with respect to major cardiovascular events or death from any cause at two years Physicians are already recommending deprescription, with 80% of general practitioners from 30 countries advising discontinuation of statin therapy in persons at least 80 years of age without cardiovascular disease who have statin-related side effects or frailty. But is it safe? That was the question asked in “Discontinuing Statins in Multimorbid Older Adults Without Cardiovascular Disease: A Randomized Noninferiority Clinical Trial (STREAM).” The multicenter noninferiority trial conducted in 24 centers in Switzerland, France and the Netherlands, randomly assigned 1,880 adults ≥70 years with at least two comorbidities without cardiovascular disease 1:1 to either discontinue statin use (intervention arm) or continue statin use (control arm). The primary endpoint compared the primary composite endpoint of major cardiovascular events (nonfatal myocardial infarction or nonfatal ischemic stroke) and all-cause death between the control and intervention groups over a follow-up of up to 48 months. Results showed that among older adults with at least two chronic conditions but no known cardiovascular disease, discontinuation of statin therapy was noninferior to continuation with respect to major cardiovascular events or death from any cause over two years. During the first two years of follow-up, 100 participants (10.7%) in the discontinuation group and 77 (8.2%) in the continuation group had a primaryoutcome event. Over the full followup period (median, 103 weeks), 119 participants (12.7%) in the discontinuation group and 87 (9.2%) in the continuation group had a primary-outcome event. Nicolas Rodondi, MD, MAS “Our findings provide information for shared decisionmaking about cautious statin discontinuation when statins are used for primary prevention only. Although deprescribing inappropriate drugs in older adults appears to be safe, the results of our trial suggest that additional randomized trials of discontinuation are needed for specific drugs,” Trial results presented in Saturday’s Late-Breaking Science session shed light on new approaches to initiating lipid-lowering therapy in secondary prevention, statin discontinuation in older adults for primary prevention, intensive blood pressure control and cardiovascular risk in people with type 2 diabetes and a novel cardiac rehabilitation. Their results found: • Starting with statin-ezetimibe combination therapy lowered LDL-C more than starting with a statin alone, but cardiovascular outcomes were similar when therapy was adjusted to reach LDL-C goals in secondary prevention. • Among older adults with at least two chronic conditions but no known cardiovascular disease, discontinuation of statin therapy is noninferior to continuation with respect to major cardiovascular events or death from any cause at two years. • Targeting a systolic blood pressure below 120 mmHg did not significantly reduce major cardiovascular events compared with a target below 140 mmHg in adults with type 2 diabetes in Brazil. • Yoga-based cardiac rehabilitation did not reduce mortality, hospitalization or stroke in patients with heart failure. See CARDIOVASCULAR, page 6

RkJQdWJsaXNoZXIy MjI2NjI=